谷康泰灵对维甲酸诱导大鼠颌骨骨质疏松的干预作用  

Interventional effect of bone peptide on mandibular osteoporosis induced by retinoic acid in rats

作　　者：张军芳[1] 夏永祥[1] 曹峻岭[2] 

机构地区：[1]南京医科大学附属南京第一医院检验科,江苏省南京市210006 [2]西安交通大学地方病研究所,陕西省西安市710061

出　　处：《中国临床康复》2006年第39期78-80,共3页Chinese Journal of Clinical Rehabilitation

摘　　要：目的:观察谷康泰灵对维甲酸诱导大鼠颌骨骨质疏松的影响。方法:实验于2001-03/04在西安交通大学地方病研究所动物实验室和骨软骨生化实验室完成。①选用雌性SD大鼠36只,按随机数字表法分为2组,对照组11只,模型组25只。模型组大鼠按85mg/(kg·d)维甲酸灌胃进行颌骨骨质疏松模型复制。灌胃15d后,每组随机选5只大鼠处死,进行骨组织病理形态学观察及形态计量学分析,确认模型复制成功后,进入治疗实验阶段。②实验大鼠分为4组:以上对照组中剩余的6只大鼠作为正常对照组,将模型组剩余的20只大鼠分为3组,骨质疏松组6只,谷康泰灵组8只,雌激素组6只。正常对照组和骨质疏松组均正常饲养;谷康泰灵组给予谷康泰灵注射液(主要成分为骨形态发生蛋白、多种骨生长因子及多种微量元素,由四川国泰制药有限责任公司重庆康宁制药厂生产)0.08mg/(kg·d),腹腔注射;雌激素组给予苯甲酸雌二醇(天津金耀氨基酸公司生产)50μg/只,每周3次,腹腔注射。实验大鼠治疗30d处死后,截取下颌骨磨牙段,制作苏木精-伊红染色切片,进行病理形态学观察,并在每组随机选取5只大鼠病理切片作形态计量学分析,指标包括松质骨面积比、骨小梁平均宽度及骨小梁平均间隔宽度等。结果:36只大鼠全部进入结果分析。①各组大鼠下颌骨骨组织病理形态学观察结果:造模期模型组大鼠下颌骨骨小梁稀少、变细,破骨细胞数目增多、活跃,骨髓腔扩大,对照组则可见骨小梁丰富、饱满。治疗30d后谷康泰灵组和雌激素组大鼠下颌骨骨小梁数目增多,骨小梁增宽,骨小梁间隙缩小,骨髓腔变小。而骨质疏松组大鼠骨小梁及骨小梁间隙无明显变化。②各组大鼠下颌骨骨组织形态计量学指标比较:造模期模型组大鼠下颌骨骨小梁平均宽度显著小于对照组(P<0.05),骨小梁平均间隔宽度显著大于对照组(P<0.05)。治�AIM： To investigate the effect of bone peptide on rats with mandibular osteoporosis induced by retinoic acid. METHODS： The study was carried out in the Animal Laboratory and Bone and Cartilage Biochemistry Laboratory of Institute of Endemic Disease, Xi＇an Jiao Tong University between March and April 2001. ① Thirty-six female SD rats were randomly allocated into control group （n=l 1） and model group （n=25）. The rats in model group were treated with 85 mg/kg per day of retinoic acid with gastric perfusion for 15 days to induce mandibular osteoporosis. After 15-day perfusion, 5 animals of each group were respectively executed to observe the pathomorphology and histomorphometry of the rat mandibles. After mandibular osteoporosis model was established, the experiment entered into treatment stage. ②The rats were divided into four groups： 6 remaining rats in above-mentioned control group were regarded as normal control group, and 20 remaining rats in above-mentioned model group were divided into three groups, osteoporosis group （n=6）, bone peptide treatment group （n=8） and estrogen treatment group （n=6）. The rats in normal control group and osteoporosis group were fed on normal diet as usual; bone peptide treatment group, fed on bone peptide injection （the basis of injection was bone morphogenetic protein, various growth factor and various microelement, produced by Kangning Pharmacy Factory of Chongqing, Guotai Pharmacy Limited Incorporated Company） 0.08 mg/kg per day by peritoneal injection; estrogen treatment group, fed on betaestradiol （produced by Jinyao Aminophenol Company of Tianjin）, 50 μg per rat, three times per week by peritoneal injection. Sacrificed after treatment for 30 days, mandibular molar part was removed for hematoxylin and eosin pathological section preparation. Totally 5 rats were randomly selected to measure histomorphometry, and indices included cancellous bone area/total bone area, trabecular width and trabecular separation, etc. RESULTS： Totally 36 r

关 键 词：骨质疏松/中药疗法 维甲酸 下颌骨 

分 类 号：R681.4[医药卫生—骨科学]